Other small molecule inhibitors, such as Pep-20, D4-2, and NCGC00138783, can directly block the binding of CD47 and SIRPα; [85,86,87] metformin, JQ1, and 4Mu can not only inhibit the CD47-SIRPα bond but also reduce CD47 expression at the transcriptional level [82,88,89,90]; PQ912 and SNE177 decrease CD47 expression by regulating posttranslational modification [91]; the widely used EGFR-TKI gefitinib, as a first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer, has also been shown to induce CD47 downregulation in vitro [92]. Here, EGFR is linked to non-small cell lung carcinoma.